Pan-African Journal of Health And Psychological Sciences
ISSN: 3093-4737 | www.pajhps.org
Vol.2, Issue 2 | April-June 2026

FDA Approves First-Ever Blood Test for Diagnosing Alzheimer's Disease

Aadarsh Kumar[1], Abhishek Kumar[1], Md Moidul Islam[2], Moidul Islam Judder[3], Ruhit Ashraf [4]

[1] B. Pharm Student, School of Pharmacy, Desh Bhagat University, Mandi Gobondgarh, Punjab, India

[2] Assistant Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobondgarh, Punjab, India

[3] Associate Professor, M.R. College of Pharmaceutical Sciences and Research, Bira, Balisha, North 24 pgs, 743234, WB, India

[4] Associate Professor, S. Lal Singh Memorial College of Pharmacy, Desh Bhagat University, Mandi Gobindgarh, Punjab, India

Corresponding Author*

Md Moidul Islam

Assistant Professor

School of Pharmacy, Desh Bhagat University, Mandi Gobondgarh, Punjab, India

Abstract

Alzheimer's disease is a progressive neurodegenerative disorder characterized by amyloid plaques and neurofibrillary tangles, leading to cognitive decline and dementia. With a rapidly aging global population, its prevalence is rising significantly, posing major public health challenges in countries like United States and India. Early diagnosis remains difficult due to limited awareness, high costs, and reliance on invasive or resource-intensive methods such as PET imaging and cerebrospinal fluid analysis. The recent approval by the U.S. Food and Drug Administration of the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio marks a transformative advancement in Alzheimer's diagnostics. This first-of-its-kind blood test

Kumar, A. et al. (2026). **FDA Approves First-Ever Blood Test for Diagnosing Alzheimer's Disease. Pan-African Journal of Health and Psychological Sciences. Vol 2; Issue 2. April-June 2026. https://doi.org/10.64261/9hs6aj83.**

ISSN: 3093-4737

measures key biomarkers, offering a less invasive, accessible, and cost-effective alternative for detecting disease-related changes in individuals with cognitive impairment. Clinical studies demonstrate high concordance with established diagnostic methods, supporting its role as a reliable screening tool when combined with comprehensive clinical evaluation. This innovation has significant implications for early detection, patient care planning, and healthcare system efficiency by enabling timely interventions and reducing diagnostic burden. However, limitations such as imperfect accuracy, ethical concerns, and the need for confirmatory testing remain. Overall, blood-based diagnostics represent a promising step toward more accessible, personalized, and proactive management of Alzheimer's disease, though further validation and equitable global implementation are essential.

Keywords: Alzheimer's disease, amyloid plaques, neurofibrillary tangles, cognitive decline, dementia prevalence, neuropsychological assessment

Introduction

Alzheimer's disease (AD) is defined by amyloid plaques (beta-amyloid deposits outside neurons) and neurofibrillary tangles (misfolded tau protein inside neurons), which disrupt brain cell function and lead to cell death. It is the leading cause of dementia globally and is recognized as a major public health issue. In 2025, approximately 7.2 million Americans aged 65 and older are living with Alzheimer's disease, with nearly three-quarters of them over the age of 75 and women accounting for almost two-thirds of cases, meaning about 1 in 9 seniors are affected [1]. In India, dementia impacts 7.4% of those aged 60 and above, amounting to around 8.8 million people [2]. As the population continues to age, these figures are projected to double by 2030 and triple by 2050, highlighting the growing challenge both countries face. It is marked by a gradual decline in memory and other cognitive abilities, including language, attention, executive function, and visuospatial skills, which progressively disrupt daily activities. Neuropsychiatric symptoms such as mood changes, agitation, and depression are also common. Diagnosis relies on

ISSN: 3093-4737

comprehensive neuropsychological assessments that compare cognitive performance to age- and education-matched norms, quantifying the severity of impairment.

Early detection of Alzheimer's disease is challenging due to limited public awareness and lingering stigma, which often leads to early symptoms being mistaken for normal aging. Diagnostic tests can be costly and hard to access, while the unpredictable nature of the disease makes it tough to know who will develop symptoms and when. Additionally, new testing methods need more research and validation, and early diagnosis can bring emotional and ethical concerns, highlighting the need for sensitive communication and support.

Significance of the FDA's Recent Approval

The FDA has significantly reshaped Alzheimer's care by approving innovative treatments like Leqembi (lecanemab) and Kisunla (donanemab), which target early-stage disease and aim to slow cognitive decline [3]. These antibody therapies work by reducing amyloid plaques, a key factor in Alzheimer's progression, and have shown promising results in clinical trials, including a 27% reduction in clinical decline with Leqembi [4]. The FDA also endorsed new diagnostic tools, such as a blood test comparable in accuracy to PET scans, making early detection more accessible and less invasive [5]. Additionally, the agency granted fast-track status to novel therapies like troculeucel, a cell-based immunotherapy targeting moderate Alzheimer's, reflecting a broader push to address different disease stages [6]. These regulatory advances not only accelerate drug development but also improve patient access to treatments and encourage ongoing innovation in diagnostics and therapeutics [7].

Current Diagnostic Landscape for Alzheimer's Disease

Alzheimer's has traditionally been diagnosed using PET scans, which reveal protein buildup in the brain, and spinal taps that analyze spinal fluid for Alzheimer's related biomarkers. These tests help detect the disease early, but can be invasive and costly. They offer crucial information about brain changes before symptoms appear. However, their complexity limits widespread use. Newer, less invasive methods are now being developed to improve accessibility [8].

ISSN: 3093-4737

Limitations and Accessibility Issues

While traditional diagnostic methods for Alzheimer's provide valuable insights, they have notable limitations. Procedures like spinal taps can be uncomfortable and carry risks, discouraging some patients from testing.[9] The high cost of PET scans and CSF analysis, often not fully covered by insurance, puts them out of reach for many. Availability is largely confined to major medical centers, making access difficult for those in rural or underserved communities. These tests can also be time-consuming, delaying both diagnosis and treatment. Additionally, not all patients are suitable candidates for invasive procedures, further restricting their use [10].

The Breakthrough Blood Test for Alzheimer's disease

Overview of the Approved Test

The U.S. Food and Drug Administration (FDA) has recently approved the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, marking a major advance in Alzheimer's disease diagnostics. This is the first blood test cleared to help identify Alzheimer's in adults aged 55 and older who are experiencing memory loss or cognitive decline. Unlike traditional methods that require PET scans or spinal taps, the Lumipulse test only needs a simple blood draw, making it far less invasive and much more accessible for patients[11]. Figure 1 shows how the Lumipulse blood test works.

Technology and Biomarkers Involved

The test works by measuring the concentrations of two specific proteins in the blood: phosphorylated tau (pTau217) and beta-amyloid 1-42. The ratio of these proteins serves as a reliable indicator of amyloid plaque buildup in the brain, which is a hallmark of Alzheimer's disease. This technology gives clinicians a practical tool to detect disease-related changes that often start years before symptoms become severe [12].

ISSN: 3093-4737



Figure 1: How the Lumipulse blood test works

Clinical Validation and Trials

Clinical validation involved nearly 500 adults with cognitive impairment, showing the blood test could closely match the results of PET scans or spinal fluid analysis, with high accuracy. However, the FDA emphasizes that the Lumipulse test should not be used as a stand-alone diagnostic tool. Instead, results should be interpreted alongside other clinical assessments to ensure a comprehensive and accurate diagnosis. This breakthrough offers hope for earlier, easier detection and could help guide more timely intervention for those at risk [11] .

Implications for Patients and Caregivers

Benefits of Early and Less Invasive Diagnosis

The introduction of a simple blood test for Alzheimer's disease is a game-changer for patients and their-families.

ISSN: 3093-4737

Unlike traditional diagnostic methods that often require invasive procedures or costly brain scans, this blood test is far more comfortable and accessible. Early detection means individuals can receive a diagnosis sooner, often before symptoms become severe, giving everyone involved more clarity and peace of mind [13].

Impact on Care Planning and Quality of Life

With an earlier and less invasive diagnosis, patients and caregivers gain valuable time to plan for the future. Families can create personalized care strategies, arrange for necessary resources, and explore treatment options that may help slow the disease's progression. Early knowledge also allows patients to participate in important decisions about their care and legal matters while they are still able [13].

Broader Impact on Healthcare Systems

Cost-Effectiveness

The new blood-based test for Alzheimer's is a cost-effective alternative to expensive PET scans and spinal taps. Its affordability makes early detection accessible to more people, easing the financial burden on patients and healthcare systems. This allows for broader, timely intervention.

Potential to Ease Burden on Neurology Services

Neurology clinics often struggle with high demand for complex diagnostics, leading to long waits and strained resources. Using a blood test as the first screening step helps quickly identify who needs further evaluation. This streamlines care and lets specialists focus on advanced cases [14] .

Integration into Routine Clinical Practice

Incorporating this test into regular checkups is practical and straightforward for primary care. Early identification of at-risk individuals means faster referrals and better symptom management. Ultimately, this integration leads to improved outcomes for those living with Alzheimer's [14].

ISSN: 3093-4737

Cautions and Considerations

Limitations of the Test

The new Alzheimer's blood test is a valuable screening tool but not a definitive diagnosis, as its accuracy isn't perfect and other health factors can influence results. It should be used alongside other clinical assessments for a complete evaluation [14] .

Ethical and Psychological Concerns

Learning about a potential Alzheimer's diagnosis can be deeply unsettling, often bringing anxiety and concerns about privacy, insurance, and relationships. Sensitive support and open, compassionate communication are vital to help families navigate these emotional and practical challenges [15].

Need for Confirmatory Diagnostics

Given the limitations of the blood test, it's essential to use it as one part of a comprehensive diagnostic process. If the result is positive, further evaluations like cognitive assessments, brain imaging, or cerebrospinal fluid analysis should follow to ensure an accurate Alzheimer's diagnosis and the best possible care.

Future Prospects

Alzheimer's diagnostics are advancing with blood-based tests that measure biomarkers like MTBR-tau243 and acetyl-L-carnitine to detect and assess disease severity. These innovations promise earlier diagnosis and personalized treatment. However, global accessibility remains limited, with most developments focused on high-income regions. Expanding research to include underserved populations and improving infrastructure is essential. As these tests evolve, they will play a key role in tailoring therapies and transforming Alzheimer's care into a more proactive, individualized approach.

ISSN: 3093-4737

Conclusion: The development of blood-based tests for Alzheimer's is a hopeful breakthrough, making-early diagnosis more accessible and less invasive. While these tests bring many advantages, they should be used alongside other diagnostic methods to ensure accuracy. Early detection can help patients and families prepare, access support, and improve their quality of life. Still, challenges like test limitations, emotional impact, and unequal access need to be addressed. Ongoing research and compassionate care are key to unlocking the full benefits of these advances. Together, better diagnostics and personalized treatment can lead to improved outcomes for those affected by Alzheimer's.

References:

1. *2025 Alzheimer's disease facts and figures.* Alzheimers Dement, 2025. **21**(4).
2. Lee, J., et al., *Prevalence of dementia in India: National and state estimates from a nationwide study.* Alzheimers Dement, 2023. **19**(7): p. 2898-2912.
3. Abdul Manap, A.S., et al., *Alzheimer's disease: A review on the current trends of the effective diagnosis and therapeutics.* Frontiers in Aging Neuroscience, 2024. **16**: p. 1429211.
4. Meidina, A.N., et al., *Effectiveness and safety of the monoclonal antibody drug lecanemab (Leqembi) in reducing beta-amyloid plaques in alzheimer's dementia: a literature review.* Journal of Health Management and Pharmacy Exploration, 2025. **3**(1).
5. Smailagic, N., et al., *18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).* The Cochrane database of systematic reviews, 2015. **2015**(1): p. CD010632.
6. Panwar, A., et al., *Emerging Novel therapeutic approaches for the treatment of Alzheimer's disease.* Advances in Alzheimer's Disease, 2024. **13**(3): p. 65-94.
7. Dokholyan, N.V., R.C. Mohs, and R.J. Bateman, *Challenges and progress in research, diagnostics, and therapeutics in Alzheimer's disease and related dementias.* Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2022. **8**(1): p. e12330.

ISSN: 3093-4737

8. Dark, H.E., M.R. Duggan, and K.A. Walker, *Plasma biomarkers for Alzheimer's and related dementias: A review and outlook for clinical neuropsychology.* Archives of Clinical Neuropsychology, 2024. **39**(3): p. 313-324.
9. Gibbs, D., *Dispatches from the Land of Alzheimer's*. 2024: Cambridge University Press.
10. Ashford, M.T., et al., *The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: a systematic review of the prediction of brain amyloid status.* Alzheimer's & Dementia, 2021. **17**(5): p. 866-887.
11. Arranz, J., et al., *Correction: Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease.* Alzheimer's Research & Therapy, 2024. **16**: p. 168.
12. Wang, J., et al., *Diagnostic accuracy of plasma p-tau217/Aβ42 for Alzheimer's disease in clinical and community cohorts.* Alzheimer's & Dementia, 2025. **21**(3): p. e70038.
13. Juganavar, A., A. Joshi, and T. Shegekar, *Navigating early Alzheimer's diagnosis: a comprehensive review of diagnostic innovations.* Cureus, 2023. **15**(9).
14. Karikari, T.K., *Blood tests for Alzheimer's disease: increasing efforts to expand and diversify research participation is critical for widespread validation and acceptance.* Journal of Alzheimer's Disease, 2022. **90**(3): p. 967-974.
15. Largent, E.A., et al., *'That would be dreadful': The ethical, legal, and social challenges of sharing your Alzheimer's disease biomarker and genetic testing results with others.* Journal of Law and the Biosciences, 2021. **8**(1): p. lsab004.